Therefore, OX40-OX40L constitute an important therapeutic target of asthma, and blockade of OX40L could disrupt TSLP-driven helper type 2 cells-related airway inflammation, thus diminish severe allergic symptoms [27]. This evidence concerns the gene TNFRSF4 and asthma.